Bruker (NASDAQ:BRKR) Reaches New 52-Week Low - What's Next?

Bruker Co. (NASDAQ:BRKR - Get Free Report)'s share price hit a new 52-week low on Friday . The stock traded as low as $43.51 and last traded at $43.82, with a volume of 290690 shares changing hands. The stock had previously closed at $44.47.

Analyst Ratings Changes

BRKR has been the subject of several recent analyst reports. Bank of America increased their price target on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. UBS Group initiated coverage on shares of Bruker in a research note on Tuesday, December 10th. They set a "neutral" rating and a $66.00 target price on the stock. Barclays reduced their price target on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Stifel Nicolaus dropped their target price on Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a report on Friday, February 14th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $70.50.

Bruker Trading Down 2.8 %

The firm has a 50 day moving average price of $51.43 and a two-hundred day moving average price of $57.35. The firm has a market capitalization of $6.56 billion, a P/E ratio of 56.90, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Remove Ads

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. On average, equities research analysts expect that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date is Monday, March 17th. Bruker's dividend payout ratio is 26.32%.

Institutional Trading of Bruker

Hedge funds have recently modified their holdings of the business. True Wealth Design LLC raised its position in Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock valued at $36,000 after buying an additional 510 shares during the period. Eagle Bay Advisors LLC increased its holdings in shares of Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock valued at $41,000 after purchasing an additional 674 shares during the period. UMB Bank n.a. lifted its position in shares of Bruker by 37.5% in the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after purchasing an additional 248 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Bruker by 47.5% during the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock worth $75,000 after purchasing an additional 412 shares during the period. Finally, Quadrant Capital Group LLC grew its position in Bruker by 18.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after purchasing an additional 196 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.